MX2016004678A - Composiciones para el tratamiento del cancer. - Google Patents

Composiciones para el tratamiento del cancer.

Info

Publication number
MX2016004678A
MX2016004678A MX2016004678A MX2016004678A MX2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A
Authority
MX
Mexico
Prior art keywords
compositions
methods
treating cancer
treatment
cancer
Prior art date
Application number
MX2016004678A
Other languages
English (en)
Spanish (es)
Inventor
A Toretsky Jeffrey
Uren Aykut
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of MX2016004678A publication Critical patent/MX2016004678A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/38Oxygen atoms in positions 2 and 3, e.g. isatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016004678A 2013-10-24 2014-10-20 Composiciones para el tratamiento del cancer. MX2016004678A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361895308P 2013-10-24 2013-10-24
PCT/US2014/061418 WO2015061229A1 (en) 2013-10-24 2014-10-20 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
MX2016004678A true MX2016004678A (es) 2017-03-10

Family

ID=52993423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004678A MX2016004678A (es) 2013-10-24 2014-10-20 Composiciones para el tratamiento del cancer.

Country Status (11)

Country Link
US (2) US9511050B2 (https=)
EP (1) EP3060207A4 (https=)
JP (1) JP6389884B2 (https=)
KR (1) KR20160065986A (https=)
CN (1) CN105848654B (https=)
AU (1) AU2014340398A1 (https=)
CA (1) CA2927148A1 (https=)
IL (1) IL245281A0 (https=)
MX (1) MX2016004678A (https=)
RU (1) RU2016114498A (https=)
WO (1) WO2015061229A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232310B2 (en) * 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
CN107011242B (zh) 2012-04-12 2020-08-07 乔治城大学 用于治疗尤文肉瘤家族肿瘤的方法和组合物
AU2014340398A1 (en) * 2013-10-24 2016-06-09 Georgetown University Methods and compositions for treating cancer
CN107108580B (zh) 2014-10-09 2020-06-30 英克特诺治疗公司 吲哚酮化合物及其用途
HUE061448T2 (hu) 2014-11-16 2023-07-28 Array Biopharma Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája
KR102277538B1 (ko) * 2015-06-08 2021-07-14 주식회사 대웅제약 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물
CN108697708A (zh) 2015-10-26 2018-10-23 洛克索肿瘤学股份有限公司 Trk抑制剂抗性癌症中的点突变以及与此相关的方法
EP3795563B1 (en) 2016-03-31 2024-07-17 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
ES2987474T3 (es) 2016-04-04 2024-11-15 Loxo Oncology Inc Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
ES2836222T3 (es) 2016-05-18 2021-06-24 Loxo Oncology Inc Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10613088B2 (en) * 2016-06-12 2020-04-07 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
US10761081B2 (en) * 2016-06-12 2020-09-01 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
CA3029851A1 (en) 2016-07-29 2018-02-01 Oncternal Therapeutics, Inc. Uses of indoline compounds such as tk216 for the treatment of cancer
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN110431241B (zh) * 2017-02-28 2024-04-19 梅约医学教育与研究基金会 检测前列腺癌
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110845389A (zh) * 2019-10-17 2020-02-28 袁健 一种新型i型拓扑异构酶抑制剂
CN114057626B (zh) * 2021-12-07 2023-06-30 山东第一医科大学(山东省医学科学院) 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物
WO2026009227A1 (en) 2024-07-04 2026-01-08 Yeda Research And Development Co. Ltd. Compositions for downregulating zeb2 in macrophages and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU583793B2 (en) 1983-07-22 1989-05-11 Du Pont Pharmaceuticals Company Phenylquinolinecarboxylic acids and derivatives as antitumor agents
EP1135123B1 (en) 1998-12-04 2004-12-29 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
US7674778B2 (en) 2004-04-30 2010-03-09 Alnylam Pharmaceuticals Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
US20090217390A1 (en) 2005-04-29 2009-08-27 Fernando Lecanda Cordero Non-human animal sarcoma model
CA2953987A1 (en) * 2006-12-29 2008-07-10 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
MX2009011281A (es) 2007-04-20 2010-03-08 Univ New York State Res Found Benzimidazol y composiciones farmaceuticas del mismo.
US20130259927A1 (en) * 2012-04-02 2013-10-03 Gradalis, Inc. Ewing's Sarcoma Bifunctional shRNA Design
CN107011242B (zh) 2012-04-12 2020-08-07 乔治城大学 用于治疗尤文肉瘤家族肿瘤的方法和组合物
AU2014340398A1 (en) * 2013-10-24 2016-06-09 Georgetown University Methods and compositions for treating cancer

Also Published As

Publication number Publication date
US20160263086A1 (en) 2016-09-15
EP3060207A1 (en) 2016-08-31
US9511050B2 (en) 2016-12-06
JP6389884B2 (ja) 2018-09-12
JP2016534084A (ja) 2016-11-04
CN105848654A (zh) 2016-08-10
CN105848654B (zh) 2018-10-02
AU2014340398A1 (en) 2016-06-09
IL245281A0 (en) 2016-06-30
WO2015061229A1 (en) 2015-04-30
CA2927148A1 (en) 2015-04-30
RU2016114498A3 (https=) 2018-08-13
US20170157089A1 (en) 2017-06-08
KR20160065986A (ko) 2016-06-09
EP3060207A4 (en) 2017-04-12
RU2016114498A (ru) 2017-11-29

Similar Documents

Publication Publication Date Title
MX2016004678A (es) Composiciones para el tratamiento del cancer.
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
MX2016002974A (es) Eteres de arilo y sus usos.
SG11201510751YA (en) Composition and vaccine for treating prostate cancer
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
MX370573B (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
MX2015009209A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos.
PH12016500164B1 (en) Therapeutically active compounds and their methods of use
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
TW201611843A (en) Methods of treatment with arginine deiminase
PH12018502569A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
GEAP201913925A (en) Compositions and methods for treating surface wounds
IN2014DN09228A (https=)
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
NZ628433A (en) Chitosan-derived compositions
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
EA032501B9 (ru) Способы и композиции для содействия заживлению острой раны и хронической раны
MX2015013021A (es) 5-bromo-indirrubinas.
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
MX369455B (es) Métodos mejorados para tratamiento de grano con ozono.